<p>Farther Finance Advisors LLC 在最近向证券交易委员会的披露中表示，在第二季度将其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的股份增加了 107.4%。该公司在本季度额外购买了 2,337 股后，持有该公司 4,512 股股票。截至其最近向证券交易委员会的备案，Farther Finance Advisors LLC 在 Cencora 的持股价值为 1,353,000 美元。</p>
<ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也买卖了该公司的股票。Net Worth Advisory Group 在第一季度将其在 Cencora 的持股增加了 1.4%。Net Worth Advisory Group 现在拥有 2,645 股该公司的股票，价值 736,000 美元，在此期间额外购买了 36 股。Obermeyer Wealth Partners 在第一季度将其在 Cencora 的持股增加了 1.3%。Obermeyer Wealth Partners 现在拥有 2,724 股该公司的股票，价值 758,000 美元，在此期间额外购买了 36 股。Grove Bank &amp; Trust 在第二季度将其在 Cencora 的持股增加了 4.3%。Grove Bank &amp; Trust 现在拥有 879 股该公司的股票，价值 264,000 美元，在此期间额外购买了 36 股。Cromwell Holdings LLC 在第一季度将其在 Cencora 的持股增加了 9.5%。Cromwell Holdings LLC 现在拥有 450 股该公司的股票，价值 125,000 美元，在此期间额外购买了 39 股。最后，Contravisory Investment Management Inc. 在第二季度将其在 Cencora 的持股增加了 0.7%。Contravisory Investment Management Inc. 现在拥有 5,382 股该公司的股票，价值 1,614,000 美元，在此期间额外购买了 40 股。97.52% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>一些分析师最近对 COR 股票发布了报告。摩根士丹利在 7 月 16 日的研究报告中将 Cencora 的目标价设定为 330.00 美元，并给予该公司 “持平” 评级。Jefferies Financial Group 将 Cencora 的目标价从 275.00 美元上调至 300.00 美元，并在 6 月 30 日的研究报告中给予该公司 “持有” 评级。最后，富国银行将 Cencora 的目标价从 337.00 美元上调至 354.00 美元，并在 8 月 13 日的研究报告中给予该公司 “增持” 评级。九位股票研究分析师对该股票给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 311.25 美元。</p>
<ul>
<li>Walgreens 股票上涨：WBA 可能成为强劲买入的 4 个理由</li>
</ul>
<p><strong>查看我们对 Cencora 的最新分析</strong></p>
<h2>内部交易活动</h2>
<p>在其他消息中，董事长 Steven H. Collis 于 9 月 16 日星期二出售了 31,350 股该公司的股票。股票以平均价格 289.86 美元出售，总交易额为 9,087,111.00 美元。交易后，董事长在公司中持有 305,913 股，价值 88,671,942.18 美元。这代表其持股减少了 9.30%。该交易在向 SEC 的法律文件中披露，相关文件可通过此超链接获取。此外，首席执行官 Robert P. Mauch 于 9 月 18 日星期四出售了 5,097 股该公司的股票。股票以平均价格 290.00 美元出售，总交易额为 1,478,130.00 美元。交易后，首席执行官在公司中持有 39,274 股，价值约 11,389,460 美元。此交易代表其持股减少了 11.49%。该销售的披露信息可以在这里找到。在过去的 90 天内，内部人士已出售了价值 16,292,923 美元的 55,993 股公司股票。公司内部人士持有 10.80% 的公司股票。</p>
<h2>Cencora 股票表现</h2>
<ul>
<li>Teva Pharma 是重新崛起的仿制药的投资方式</li>
</ul>
<p>Cencora 股票在星期三开盘价为 301.95 美元。该公司的市值为 585.4 亿美元，市盈率为 31.06，市盈增长比率为 1.47，贝塔值为 0.62。该公司的债务与股本比率为 3.64，速动比率为 0.53，流动比率为 0.90。该公司的 50 日简单移动平均为 292.41 美元，200 日简单移动平均为 287.63 美元。Cencora, Inc. 的一年低点为 218.65 美元，一年高点为 309.35 美元。</p>
<p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近于 8 月 6 日星期三公布了其财报。该公司报告季度每股收益为 4.00 美元，超出分析师共识预期的 3.79 美元，超出幅度为 0.21 美元。该业务在本季度的收入为 806.6 亿美元，而共识预期为 803.4 亿美元。Cencora 的净利润率为 0.60%，股本回报率为 267.36%。该公司的收入同比增长 8.7%。在去年同期，该公司每股收益为 3.34 美元。研究分析师预计 Cencora, Inc. 在当前财政年度将发布 15.37 美元的每股收益。</p>
<h2>Cencora 股息公告</h2>
<p>该公司最近还披露了季度股息，已于 9 月 3 日星期三支付。8 月 15 日星期五的股东获得每股 0.55 美元的股息。除息日期为 8 月 15 日星期五。这代表每年 2.20 美元的股息和 0.7% 的股息收益率。Cencora 的股息支付比率为 22.63%。</p>
<h2>Cencora 公司简介</h2>
<p>（免费报告）</p>
<p>Cencora, Inc. 负责药品的采购和分销。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代地点药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配备和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票比 Cencora 更好</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>3 只量子计算 ETF 值得关注——而且为什么其中 2 只不持有 D-Wave</li>
<li>股票市场升级：它们是什么？</li>
<li>忘掉关税，Landstar 和 West Fraser 仍然可以反弹</li>
<li>日经 225 指数是什么？</li>
<li>超级微型公司会是下一个大规模 AI 收购的对象吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
<p>在你考虑 Cencora 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cencora 并不在名单上。</p>
<p>虽然 Cencora 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Farther Finance Advisors LLC 在第二季度将其在 Cencora, Inc. (NYSE:COR) 的持股增加了 107.4%，额外购买了 2,337 股，总持股达到 4,512 股，价值 135 万美元。其他机构投资者也增加了他们的持股。分析师为 Cencora 设置的共识目标价为 311.25 美元，评级为 “适度买入”。最近的内部交易包括董事长 Steven H. Collis 和首席执行官 Robert P. Mauch，他们出售了大量股份。Cencora 的股票开盘价为 301.95 美元，市值为 585.4 亿美元，市盈率为 31.06</p>

<p>Farther Finance Advisors LLC boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 107.4% in the 2nd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 4,512 shares of the company's stock after buying an additional 2,337 shares during the quarter. Farther Finance Advisors LLC's holdings in Cencora were worth $1,353,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Farther Finance Advisors LLC 在最近向证券交易委员会的披露中表示，在第二季度将其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的股份增加了 107.4%。该公司在本季度额外购买了 2,337 股后，持有该公司 4,512 股股票。截至其最近向证券交易委员会的备案，Farther Finance Advisors LLC 在 Cencora 的持股价值为 1,353,000 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently bought and sold shares of the company. Net Worth Advisory Group boosted its stake in Cencora by 1.4% during the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after buying an additional 36 shares during the period. Obermeyer Wealth Partners boosted its stake in Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock worth $758,000 after buying an additional 36 shares during the period. Grove Bank &amp; Trust boosted its stake in Cencora by 4.3% during the second quarter. Grove Bank &amp; Trust now owns 879 shares of the company's stock worth $264,000 after buying an additional 36 shares during the period. Cromwell Holdings LLC boosted its stake in Cencora by 9.5% during the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after buying an additional 39 shares during the period. Finally, Contravisory Investment Management Inc. boosted its stake in Cencora by 0.7% during the second quarter. Contravisory Investment Management Inc. now owns 5,382 shares of the company's stock worth $1,614,000 after buying an additional 40 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也买卖了该公司的股票。Net Worth Advisory Group 在第一季度将其在 Cencora 的持股增加了 1.4%。Net Worth Advisory Group 现在拥有 2,645 股该公司的股票，价值 736,000 美元，在此期间额外购买了 36 股。Obermeyer Wealth Partners 在第一季度将其在 Cencora 的持股增加了 1.3%。Obermeyer Wealth Partners 现在拥有 2,724 股该公司的股票，价值 758,000 美元，在此期间额外购买了 36 股。Grove Bank &amp; Trust 在第二季度将其在 Cencora 的持股增加了 4.3%。Grove Bank &amp; Trust 现在拥有 879 股该公司的股票，价值 264,000 美元，在此期间额外购买了 36 股。Cromwell Holdings LLC 在第一季度将其在 Cencora 的持股增加了 9.5%。Cromwell Holdings LLC 现在拥有 450 股该公司的股票，价值 125,000 美元，在此期间额外购买了 39 股。最后，Contravisory Investment Management Inc. 在第二季度将其在 Cencora 的持股增加了 0.7%。Contravisory Investment Management Inc. 现在拥有 5,382 股该公司的股票，价值 1,614,000 美元，在此期间额外购买了 40 股。97.52% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of analysts have recently issued reports on COR shares. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the company an &#34;equal weight&#34; rating in a research note on Wednesday, July 16th. Jefferies Financial Group boosted their target price on shares of Cencora from $275.00 to $300.00 and gave the company a &#34;hold&#34; rating in a research note on Monday, June 30th. Finally, Wells Fargo &amp; Company boosted their target price on shares of Cencora from $337.00 to $354.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, August 13th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $311.25.</p>
<div class="lb-trans"><p>一些分析师最近对 COR 股票发布了报告。摩根士丹利在 7 月 16 日的研究报告中将 Cencora 的目标价设定为 330.00 美元，并给予该公司 “持平” 评级。Jefferies Financial Group 将 Cencora 的目标价从 275.00 美元上调至 300.00 美元，并在 6 月 30 日的研究报告中给予该公司 “持有” 评级。最后，富国银行将 Cencora 的目标价从 337.00 美元上调至 354.00 美元，并在 8 月 13 日的研究报告中给予该公司 “增持” 评级。九位股票研究分析师对该股票给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 311.25 美元。</p>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票上涨：WBA 可能成为强劲买入的 4 个理由</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on Cencora</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Cencora 的最新分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, Chairman Steven H. Collis sold 31,350 shares of the company's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company's stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the transaction, the chief executive officer owned 39,274 shares in the company, valued at approximately $11,389,460. This trade represents a 11.49% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,993 shares of company stock worth $16,292,923. Corporate insiders own 10.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，董事长 Steven H. Collis 于 9 月 16 日星期二出售了 31,350 股该公司的股票。股票以平均价格 289.86 美元出售，总交易额为 9,087,111.00 美元。交易后，董事长在公司中持有 305,913 股，价值 88,671,942.18 美元。这代表其持股减少了 9.30%。该交易在向 SEC 的法律文件中披露，相关文件可通过此超链接获取。此外，首席执行官 Robert P. Mauch 于 9 月 18 日星期四出售了 5,097 股该公司的股票。股票以平均价格 290.00 美元出售，总交易额为 1,478,130.00 美元。交易后，首席执行官在公司中持有 39,274 股，价值约 11,389,460 美元。此交易代表其持股减少了 11.49%。该销售的披露信息可以在这里找到。在过去的 90 天内，内部人士已出售了价值 16,292,923 美元的 55,993 股公司股票。公司内部人士持有 10.80% 的公司股票。</p>
</div><h2>Cencora Stock Performance</h2>
<div class="lb-trans"><h2>Cencora 股票表现</h2>
</div><ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma 是重新崛起的仿制药的投资方式</li>
</ul>
</div><p>Shares of Cencora stock opened at $301.95 on Wednesday. The company has a market capitalization of $58.54 billion, a PE ratio of 31.06, a P/E/G ratio of 1.47 and a beta of 0.62. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The company has a 50-day simple moving average of $292.41 and a two-hundred day simple moving average of $287.63. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35.</p>
<div class="lb-trans"><p>Cencora 股票在星期三开盘价为 301.95 美元。该公司的市值为 585.4 亿美元，市盈率为 31.06，市盈增长比率为 1.47，贝塔值为 0.62。该公司的债务与股本比率为 3.64，速动比率为 0.53，流动比率为 0.90。该公司的 50 日简单移动平均为 292.41 美元，200 日简单移动平均为 287.63 美元。Cencora, Inc. 的一年低点为 218.65 美元，一年高点为 309.35 美元。</p>
</div><p>Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts' consensus estimates of $3.79 by $0.21. The business had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 earnings per share. Research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近于 8 月 6 日星期三公布了其财报。该公司报告季度每股收益为 4.00 美元，超出分析师共识预期的 3.79 美元，超出幅度为 0.21 美元。该业务在本季度的收入为 806.6 亿美元，而共识预期为 803.4 亿美元。Cencora 的净利润率为 0.60%，股本回报率为 267.36%。该公司的收入同比增长 8.7%。在去年同期，该公司每股收益为 3.34 美元。研究分析师预计 Cencora, Inc. 在当前财政年度将发布 15.37 美元的每股收益。</p>
</div><h2>Cencora Dividend Announcement</h2>
<div class="lb-trans"><h2>Cencora 股息公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora's dividend payout ratio is 22.63%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，已于 9 月 3 日星期三支付。8 月 15 日星期五的股东获得每股 0.55 美元的股息。除息日期为 8 月 15 日星期五。这代表每年 2.20 美元的股息和 0.7% 的股息收益率。Cencora 的股息支付比率为 22.63%。</p>
</div><h2>Cencora Company Profile</h2>
<div class="lb-trans"><h2>Cencora 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p>
<div class="lb-trans"><p>Cencora, Inc. 负责药品的采购和分销。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代地点药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配备和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>3 Quantum Computing ETFs to Know—And Why 2 Don't Hold D-Wave</li>
<li>Stock Market Upgrades: What Are They?</li>
<li>Forget Tariffs, Landstar and West Fraser Can Still Rally</li>
<li>What is the Nikkei 225 index?</li>
<li>Is Super Micro Next in Line for a Big AI Takeover?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Cencora 更好</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>3 只量子计算 ETF 值得关注——而且为什么其中 2 只不持有 D-Wave</li>
<li>股票市场升级：它们是什么？</li>
<li>忘掉关税，Landstar 和 West Fraser 仍然可以反弹</li>
<li>日经 225 指数是什么？</li>
<li>超级微型公司会是下一个大规模 AI 收购的对象吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cencora 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cencora 并不在名单上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cencora 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Farther Finance Advisors LLC 收购了 Cencora, Inc. 的 2,337 股股票 $COR